Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Cash (2016 - 2025)

Historic Change in Cash for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $14.8 million.

  • Vanda Pharmaceuticals' Change in Cash rose 71522.81% to $14.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$17.5 million, marking a year-over-year increase of 4787.35%. This contributed to the annual value of -$17.5 million for FY2025, which is 4787.35% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Change in Cash stood at $14.8 million for Q4 2025, which was up 71522.81% from -$11.0 million recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Change in Cash peaked at $219.1 million during Q1 2023, and registered a low of -$204.1 million during Q2 2023.
  • For the 5-year period, Vanda Pharmaceuticals' Change in Cash averaged around $1.2 million, with its median value being -$4.6 million (2021).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Change in Cash soared by 542821.17% in 2022, and later tumbled by 224562.79% in 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Change in Cash (Quarter) stood at $1.5 million in 2021, then surged by 5428.21% to $85.6 million in 2022, then crashed by 155.31% to -$47.4 million in 2023, then skyrocketed by 103.84% to $1.8 million in 2024, then soared by 715.23% to $14.8 million in 2025.
  • Its Change in Cash stands at $14.8 million for Q4 2025, versus -$11.0 million for Q3 2025 and -$30.8 million for Q2 2025.